GX 427 has begun evaluation in Phase 1 clinical studies, while
the third product candidate, OGX-225, has completed preclinical
pharmacology studies. More information is available at
http://www.oncogenex.ca.
CONTACT: OncoGenex Contact: Scott Cormack, President & CEO, (604)
805-2274, scormack@oncogenex.ca; OncoGenex Media Contact: Jason Spark,
Porter Novelli Life Sciences, (619) 849-6005, jspark@pnlifesciences.com
'/>"/>SOURCE OncoGenex Technologies Inc. Copyright©2008 PR Newswire. All rights reserved | |
Page: 1 2 3 4 Related biology technology :1.
EpiCept Reports Expansion of Clinical Development For Licensed Cancer Compound2.
QMed, Inc. Reports July Medicare SNP Enrollments3.
Phlo Affiliate Reports Expanded Coverage to Oregon Border4.
Healthcare Technologies Reports Loss for 2007 Second Quarter & Six Months Results5.
Dragon Pharmaceutical Reports Growth in Sales and Profits during Second Quarter of 20076.
Carrington Reports Second Quarter 2007 Results7.
Avitar Reports Third Quarter Financial Results for Fiscal 20078.
Response Genetics Reports Second Quarter 2007 Financial Results9.
Cadence Pharmaceuticals Reports Second Quarter 2007 Financial Results10.
Transgenomic, Inc. Reports Second Quarter 2007 Results11.
Pressure BioSciences, Inc. Reports Second Quarter 2007 Financial Results and Provides Business Update